Download PDF
Rofo 2020; 192(02): 171-182
DOI: 10.1055/a-1001-2412
Oncologic Imaging
© Georg Thieme Verlag KG Stuttgart · New York

Update Bildgebung neuroendokrine Neoplasien

Article in several languages: English | deutsch
Jens Holger Figiel
1   Diagnostic & Interventional Radiology, University-Hospital of Giessen and Marburg Campus Marburg, Germany
,
Simon G. Viniol
1   Diagnostic & Interventional Radiology, University-Hospital of Giessen and Marburg Campus Marburg, Germany
,
Jannis Görlach
1   Diagnostic & Interventional Radiology, University-Hospital of Giessen and Marburg Campus Marburg, Germany
,
Anja Rinke
2   Department for Gastroenterology, University-Hospital of Giessen and Marburg Campus Marburg, Germany
,
Damiano Librizzi
3   Department for Nuclear Medicine, University-Hospital of Giessen and Marburg Campus Marburg, Germany
,
Andreas H. Mahnken
1   Diagnostic & Interventional Radiology, University-Hospital of Giessen and Marburg Campus Marburg, Germany
› Author Affiliations
Further Information

Publication History

13 April 2019

30 July 2019

Publication Date:
11 September 2019 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Hintergrund Neuroendokrine Neoplasien (NEN) sind eine sehr heterogene Gruppe von Tumoren mit Expression typischer Proteine. Es wird eine große Bandbreite radiologischer und nuklearmedizinischer Methoden benötigt, um den Krankheitsverlauf adäquat einschätzen und den Patienten optimal behandeln zu können. Das Spektrum der Fragestellungen reicht von der Detektion kleinster Primärtumoren über die Dokumentation des Metastasierungsmusters und -verlaufs bis zur Beurteilung der Eignung für bestimmte invasive bzw. nichtinvasive Therapieverfahren. Hierbei ist eine exakte Befunderfassung und -quantifizierung unerlässlich.

Methode Diese Übersicht basiert auf einer umfassenden Literaturrecherche zu den unterschiedlichen Aspekten der Bildgebung neuroendokriner Neoplasien.

Ergebnisse und Schlussfolgerung Dieser Artikel soll einen Überblick über die zur Verfügung stehenden bildgebenden Verfahren mit ihren jeweiligen Vor- und Nachteilen für die Diagnostik und ihre Wertigkeit für Verlaufskontrollen neuroendokriner Neoplasien geben. Dabei werden Empfehlungen für Untersuchungsprotokolle gegeben, typische Bildbefunde dargestellt und ein Ausblick auf zukünftige Entwicklungen gegeben.

Kernaussagen: 

  • Neuroendokrine Neoplasien sind relativ selten und stellen eine komplexe und vielgestaltige Erkrankungsgruppe dar. Langjährige Krankheitsverläufe sind auch im metastasierten Stadium nicht selten.

  • Die Diagnostik neuroendokriner Neoplasien bedient sich eines großen Spektrums komplementärer morphologischer und funktioneller Bildgebungsmethoden.

  • Eine adäquate Methodenwahl, Untersuchungsplanung und Vorbereitung des Patienten sind für ein exaktes Staging und aussagekräftige Verlaufskontrollen unerlässlich.

Zitierweise

  • Figiel JH, Viniol SG, Görlach J et al. Update Regarding Imaging of Neuroendocrine Neoplasms. Fortschr Röntgenstr 2020; 192: 171 – 182

Key words

PET-CT - CT - neoplasms - ultrasound - MR imaging
 

  • Literatur

  • 1 Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankfurter Zeitschrift für Pathologie 1907: 426-429
    PubMedGoogle Scholar
  • 2 Rindi G, Klimstra DS, Abedi-Ardekani B. et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern pathology: an official journal of the United States and Canadian Academy of Pathology Inc 2018
    PubMedGoogle Scholar
  • 3 Perren A, Couvelard A, Scoazec JY. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology 2017; 105: 196-200
    CrossrefPubMedGoogle Scholar
  • 4 Dasari A, Shen C, Halperin D. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA oncology 2017; 3: 1335-1342
    CrossrefPubMedGoogle Scholar
  • 5 Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Annals of oncology: official journal of the European Society for Medical Oncology 2013; 24: 3040-3044
    PubMedGoogle Scholar
  • 6 Yao JC, Hassan M, Phan A. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35825 cases in the United States. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008; 26: 3063-3072
    CrossrefPubMedGoogle Scholar
  • 7 Man D, Wu J, Shen Z. et al. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer management and research 2018; 10: 5629-5638
    CrossrefPubMedGoogle Scholar
  • 8 Chiti A, Fanti S, Savelli G. et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. European journal of nuclear medicine 1998; 25: 1396-1403
    CrossrefPubMedGoogle Scholar
  • 9 Fan Z, Li Y, Yan K. et al. Application of contrast-enhanced ultrasound in the diagnosis of solid pancreatic lesions--a comparison of conventional ultrasound and contrast-enhanced CT. European journal of radiology 2013; 82: 1385-1390
    CrossrefPubMedGoogle Scholar
  • 10 Rösch T, Lightdale CJ, Botet JF. et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. The New England journal of medicine 1992; 326: 1721-1726
    CrossrefPubMedGoogle Scholar
  • 11 Ardengh JC, Rosenbaum P, Ganc AJ. et al. Role of EUS in the preoperative localization of insulinomas compared with spiral CT. Gastrointestinal endoscopy 2000; 51: 552-555
    CrossrefPubMedGoogle Scholar
  • 12 Anderson MA, Carpenter S, Thompson NW. et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. The American journal of gastroenterology 2000; 95: 2271-2277
    CrossrefPubMedGoogle Scholar
  • 13 Prakashini K, Kakkar C, Sambhaji C. et al. Quantitative and qualitative bowel analysis using mannitol, water and iodine-based endoluminal contrast agent on 64-row detector CT. The Indian journal of radiology & imaging 2013; 23: 373-378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Ichikawa T, Okada M, Kondo H. et al. Recommended iodine dose for multiphasic contrast-enhanced mutidetector-row computed tomography imaging of liver for assessing hypervascular hepatocellular carcinoma: multicenter prospective study in 77 general hospitals in Japan. Academic radiology 2013; 20: 1130-1136
    CrossrefPubMedGoogle Scholar
  • 15 Cloyd JM, Kopecky KE, Norton JA. et al. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. Surgery 2016; 160: 708-713
    CrossrefPubMedGoogle Scholar
  • 16 Elias D, Lefevre JH, Duvillard P. et al. Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Annals of surgery 2010; 251: 307-310
    CrossrefPubMedGoogle Scholar
  • 17 Ruf J, Schiefer J, Furth C. et al. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2011; 52: 697-704
    PubMedGoogle Scholar
  • 18 Veit-Haibach P, Schiesser M, Soyka J. et al. Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component. European radiology 2011; 21: 256-264
    CrossrefPubMedGoogle Scholar
  • 19 Kumbasar B, Kamel IR, Tekes A. et al. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdominal imaging 2004; 29: 696-702
    CrossrefPubMedGoogle Scholar
  • 20 Ambrosini V, Nanni C, Zompatori M. et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. European journal of nuclear medicine and molecular imaging 2010; 37: 722-727
    CrossrefPubMedGoogle Scholar
  • 21 Zamboni GA, Bernardin L, Pozzi Mucelli R. Dynamic MDCT of the pancreas: is time-density curve morphology useful for the differential diagnosis of solid lesions? A preliminary report. European journal of radiology 2012; 81: e381-e385
    CrossrefPubMedGoogle Scholar
  • 22 d’Assignies G, Couvelard A, Bahrami S. et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 2009; 250: 407-416
    CrossrefPubMedGoogle Scholar
  • 23 Johanssen S, Boivin M, Lochs H. et al. The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. Gastrointestinal endoscopy 2006; 63: 660-665
    CrossrefPubMedGoogle Scholar
  • 24 Pilleul F, Penigaud M, Milot L. et al. Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis. Radiology 2006; 241: 796-801
    CrossrefPubMedGoogle Scholar
  • 25 Seemann MD. Detection of metastases from gastrointestinal neuroendocrine tumors: prospective comparison of 18F-TOCA PET, triple-phase CT, and PET/CT. Technology in cancer research & treatment 2007; 6: 213-220
    CrossrefPubMedGoogle Scholar
  • 26 Lee CH, Kim KA, Lee J. et al. Using low tube voltage (80kVp) quadruple phase liver CT for the detection of hepatocellular carcinoma: two-year experience and comparison with Gd-EOB-DTPA enhanced liver MRI. European journal of radiology 2012; 81: e605-e611
    CrossrefPubMedGoogle Scholar
  • 27 Ng CS, Wei W, Duran C. et al. CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents. Abdominal radiology (New York) 2018; 43: 1661-1669
    CrossrefPubMedGoogle Scholar
  • 28 S2k-Leitlinie Neuroendokrine Tumore. Zeitschrift fur Gastroenterologie 2018; 56: 583-681
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Lin XZ, Wu ZY, Tao R. et al. Dual energy spectral CT imaging of insulinoma-Value in preoperative diagnosis compared with conventional multi-detector CT. European journal of radiology 2012; 81: 2487-2494
    CrossrefPubMedGoogle Scholar
  • 30 Dromain C, de Baere T, Lumbroso J. et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2005; 23: 70-78
    CrossrefPubMedGoogle Scholar
  • 31 Masselli G, Di Tola M, Casciani E. et al. Diagnosis of Small-Bowel Diseases: Prospective Comparison of Multi-Detector Row CT Enterography with MR Enterography. Radiology 2016; 279: 420-431
    CrossrefPubMedGoogle Scholar
  • 32 Morse B, Jeong D, Thomas K. et al. Magnetic Resonance Imaging of Neuroendocrine Tumor Hepatic Metastases: Does Hepatobiliary Phase Imaging Improve Lesion Conspicuity and Interobserver Agreement of Lesion Measurements?. Pancreas 2017; 46: 1219-1224
    CrossrefPubMedGoogle Scholar
  • 33 Moryoussef F, de Mestier L, Belkebir M. et al. Impact of Liver and Whole-Body Diffusion-Weighted MRI for Neuroendocrine Tumors on Patient Management: A Pilot Study. Neuroendocrinology 2017; 104: 264-272
    CrossrefPubMedGoogle Scholar
  • 34 Löwenthal D, Zeile M, Lim WY. et al. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. European radiology 2011; 21: 832-840
    CrossrefPubMedGoogle Scholar
  • 35 Vandecaveye V, Michielsen K, de Keyzer F. et al. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology 2014; 270: 747-757
    CrossrefPubMedGoogle Scholar
  • 36 de Robertis R, D’Onofrio M, Zamboni G. et al. Pancreatic Neuroendocrine Neoplasms: Clinical Value of Diffusion-Weighted Imaging. Neuroendocrinology 2016; 103: 758-770
    CrossrefPubMedGoogle Scholar
  • 37 Wang Y, Chen ZE, Yaghmai V. et al. Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics. Journal of magnetic resonance imaging: JMRI 2011; 33: 1071-1079
    CrossrefPubMedGoogle Scholar
  • 38 Kang KM, Lee JM, Yoon JH. et al. Intravoxel incoherent motion diffusion-weighted MR imaging for characterization of focal pancreatic lesions. Radiology 2014; 270: 44-453
    PubMedGoogle Scholar
  • 39 Feng L, Huang C, Shanbhogue K. et al. RACER-GRASP: Respiratory-weighted, aortic contrast enhancement-guided and coil-unstreaking golden-angle radial sparse MRI. Magnetic resonance in medicine 2018; 80: 77-89
    CrossrefPubMedGoogle Scholar
  • 40 Kaltenbach B, Roman A, Polkowski C. et al. Free-breathing dynamic liver examination using a radial 3D T1-weighted gradient echo sequence with moderate undersampling for patients with limited breath-holding capacity. European journal of radiology 2017; 86: 26-32
    CrossrefPubMedGoogle Scholar
  • 41 Goldenberg JM, Pagel MD. Assessments of tumor metabolism with CEST MRI. NMR Biomed 2018; e3943 10.1002/nbm.3943
    PubMedGoogle Scholar
  • 42 Kim MJ, Mitchell DG, Ito K. et al. Hepatic MR imaging: comparison of 2D and 3D gradient echo techniques. Abdominal imaging 2001; 26: 269-276
    CrossrefPubMedGoogle Scholar
  • 43 Torkzad MR, Masselli G, Halligan S. et al. Indications and selection of MR enterography vs. MR enteroclysis with emphasis on patients who need small bowel MRI and general anaesthesia: results of a survey. Insights into imaging 2015; 6: 339-346
    CrossrefPubMedGoogle Scholar
  • 44 Flechsig P, Zechmann CM, Schreiweis J. et al. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET. European journal of radiology 2015; 84: 1593-1600
    CrossrefPubMedGoogle Scholar
  • 45 Hoffmann R, Thomas C, Rempp H. et al. Performing MR-guided biopsies in clinical routine: factors that influence accuracy and procedure time. European radiology 2012; 22: 663-671
    CrossrefPubMedGoogle Scholar
  • 46 Wiesli P, Brändle M, Schmid C. et al. Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. Journal of vascular and interventional radiology: JVIR 2004; 15: 1251-1256
    CrossrefPubMedGoogle Scholar
  • 47 Doppman JL, Jensen RT. Localization of gastroenteropancreatic tumours by angiography. Italian journal of gastroenterology and hepatology 1999; 31 (Suppl. 02) S163-S166
    PubMedGoogle Scholar
  • 48 Krenning EP, Kwekkeboom DJ, Bakker WH. et al. Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1- and 123I-Tyr3-octreotide: the Rotterdam experience with more than 1000 patients. European journal of nuclear medicine 1993; 20: 716-731
    CrossrefPubMedGoogle Scholar
  • 49 Sainz-Esteban A, Olmos R, González-Sagrado M. et al. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours. Nuclear medicine communications 2015; 36: 251-259
    CrossrefPubMedGoogle Scholar
  • 50 Velikyan I, Sundin A, Sörensen J. et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2014; 55: 204-210
    PubMedGoogle Scholar
  • 51 Johnbeck CB, Knigge U, Loft A. et al. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2017; 58: 451-457
    PubMedGoogle Scholar
  • 52 Antwi K, Fani M, Heye T. et al. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. European journal of nuclear medicine and molecular imaging 2018; 45: 2318-2327
    CrossrefPubMedGoogle Scholar
  • 53 Binderup T, Knigge U, Loft A. et al. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clinical cancer research: an official journal of the American Association for Cancer Research 2010; 16: 978-985
    CrossrefPubMedGoogle Scholar
  • 54 Gaertner FC, Beer AJ, Souvatzoglou M. et al. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors. Investigative radiology 2013; 48: 263-272
    CrossrefPubMedGoogle Scholar
  • 55 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease 2010; 30: 52-60
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Choi H, Charnsangavej C, Faria SC. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2007; 25: 1753-1759
    CrossrefPubMedGoogle Scholar
  • 57 Vliet EI, Krenning EP, Teunissen JJ. et al. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with 177Lu-DOTA0, Tyr3octreotate. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2013; 54: 1689-1696
    PubMedGoogle Scholar